Apitope has posted phase 2a data on the multiple sclerosis drug Merck KGaA walked away from last year.

VBL Therapeutics has presented more data from a phase 2 trial of VB-111 monotherapy in thyroid cancer patients.

Cidara Therapeutics will stop work on its antifungal CD101 in women with acute VVC, after the topical candidate failed a mid-stage trial.

Pfizer said the FDA has given its experimental leukemia med inotuzumab ozogamicin a priority review as it gets to work on assessing the medication for approval.

Nordic Nanovector CEO Luigi Costa has talked up the level of third-party interest in non-Hodgkin lymphoma candidate Betalutin.

The biotech's CEO says the clinical trial is the first to show that it is possible to usher large-molecule drugs across the blood-brain barrier.

After fluffing its lines in two mid-to-late stage trials in lung and colorectal cancer over the past few years, Daiichi and ArQule had hoped that tivantinib…

Arix Biosciences has made good on its promise to raise £100 million ($127 million) in its public offering on the London Stock Exchange as it looks to put the…

Takeda and TiGenix have presented 52-week data on their stem cells in Crohn’s disease patients with treatment-refractory complex perianal fistulas.

Biotech